Top

Published in:

01-01-2021 | Vasculitis | IM - COMMENTARY

Cryoglobulinemic vasculitis: having giant steps; but there are still unanswered questions

Authors: Omer Karadag, Emine Duran

Published in: Internal and Emergency Medicine | Issue 1/2021

Excerpt

Cryoglobulinemic vasculitis (CryoVas) is a systemic immune-complex vasculitis which can be a life-threatening condition. In their article recently published by Internal and Emergency Medicine, Vacchi C et al. reported the safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of CryoVas [1]. For a better understanding of this article, an overarching look to the historical picture of CryoVas and details of the usage of biosimilars will be helpful. …

Vacchi C, Visentini M, Gragnani L et al (2020) Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar). Intern Emerg Med. https://doi.org/10.1007/s11739-020-02386-0CrossRefPubMed

Wintrobe MM, Buell MV (1933) Hyperproteinemia associated with multiple myeloma. Bull Johns Hopkins Hosp 52:156–165

Barr DP, Reader GG, Wheeler CH (1950) Cryoglobulinemia; report of two cases with discussion of clinical manifestations incidence and significance. Ann Intern Med 32(1):6–29. https://doi.org/10.7326/0003-4819-32-1-6CrossRefPubMed

Galli M, Invernizzi F, Monti G (2008) Cryoglobulinemic Vasculitis. In: Bridges SL, Ball GV (eds) Vasculitis, 2nd edn. Oxford University Press, Oxford, pp 529–545

Boleto G, Ghillani-Dalbin P, Musset L et al (2020) Cryoglobulinemia after the era of chronic hepatitis C infection. Semin Arthritis Rheum 50(4):695–700. https://doi.org/10.1016/j.semarthrit.2020.05.004CrossRefPubMed

Roccatello D, Fenoglio R, Sciascia S (2019) The dilemma of treating hepatitis C virus-associated cryoglobulinemia. Curr Opin Rheumatol 31(5):499–504. https://doi.org/10.1097/BOR.0000000000000624CrossRefPubMed

Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D (2015) Cryoglobulinemia vasculitis. Am J Med 128(9):950–955. https://doi.org/10.1016/j.amjmed.2015.02.017CrossRefPubMed

Lally L, Spiera R (2016) B-cell-targeted therapy in systemic vasculitis. Curr Opin Rheumatol 28(1):15–20. https://doi.org/10.1097/BOR.0000000000000235CrossRefPubMed

Gulácsi L, Brodszky V, Baji P, Rencz F, Péntek M (2017) The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther 34(5):1128–1144. https://doi.org/10.1007/s12325-017-0522-yCrossRefPubMedPubMedCentral

10.

Park W, Božić-Majstorović L, Milakovic D et al (2018) Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. MAbs 10(6):934–943. https://doi.org/10.1080/19420862.2018.1487912CrossRefPubMedPubMedCentral

11.

Campochiaro C, De Luca G, Lazzaroni MG et al (2020) Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keaa136CrossRef

12.

Shim SC, Božić-Majstorović L, Berrocal Kasay A et al (2019) Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. Rheumatology (Oxford) 58(12):2193–2202. https://doi.org/10.1093/rheumatology/kez152CrossRef

13.

Desbois AC, Biard L, Sène D et al (2020) Rituximab-associated vasculitis flare: incidence, predictors, and outcome. J Rheumatol 47(6):896–902. https://doi.org/10.3899/jrheum.190076CrossRefPubMed

Title: Cryoglobulinemic vasculitis: having giant steps; but there are still unanswered questions
Authors: Omer Karadag
Emine Duran
Publication date: 01-01-2021
Publisher: Springer International Publishing
Keywords: Vasculitis
Vasculitis
Rituximab
Rituximab
Published in: Internal and Emergency Medicine / Issue 1/2021
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-020-02481-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Correction to: Treat all COVID 19‑positive patients, but do not forget those negative with chronic diseases

Cancer in adult patients with inflammatory arthritis is associated with high ascending aortic stiffness and left ventricular hypertrophy and diastolic dysfunction

Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?: Comment

Correction to: COVID‑19: The crucial role of blood coagulation and fibrinolysis

An unusual cause of large bowel perforation: ingestion of a clam valve

When awareness makes the difference: diagnosing and treating the acute hepatic porphyrias

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials